Syschem (India) Ltd (SYSCHEM) — shareholding pattern, promoter holding, financials and share price
About Syschem (India) Ltd (SYSCHEM)
Syschem (India) Ltd operates in the Pharmaceuticals industry, within the Healthcare sector. It trades on the NSE as SYSCHEM and on the BSE under scrip code 531173. Its ISIN is INE121D01036.
Incorporated in 1993, Syschem (India) Limited manufactures Active Pharmaceuticals Ingredients (APIs) and bulk drugs. [1]
Syschem India Limited is a vertically integrated manufacturer of pharmaceutical APIs and intermediates based in Kalka, Haryana, producing antibiotic APIs such as amoxicillin, ampicillin, cephalexin and cephadroxil for domestic formulators and export customers across multiple continents, with an installed capacity of ~4,200 TPA and plans to expand toward 8,000 TPA.
The company reported a strong operating inflection during 9M FY25-26 with consolidated sales rising from ₹247.48 crore to ₹406.31 crore (a 65% increase), EBITDA rising more than threefold to ₹11.75 crore and PAT swinging to a positive ₹7.74 crore for 9M, reflecting material operating leverage from higher volumes and improved product mix.
Listed peers in Pharmaceuticals: Nectar Lifescience Ltd, Kerala Ayurveda Ltd, Coral Laboratories Ltd, Brooks Laboratories Ltd, Gujarat Inject (Kerala) Ltd, Achyut Healthcare Ltd.
Valuation & Returns
10 Jul 2026At ₹42.5 a share on 10 Jul 2026, Syschem (India) Ltd (SYSCHEM) was valued at a price-to-earnings ratio of 24.04x against an industry P/E of 36.41x and a price-to-book of 2.5x on a book value of ₹17.03 per share as of Mar 2025. Solomo computes return on equity of 10.38% and return on capital employed of 18.68% from filed results. Earnings ratios use standalone results for the twelve months Jun 2025 to Mar 2026.
- P/E
- 24.04x
- Industry P/E
- 36.41x
- P/B
- 2.5x
- EPS (TTM)
- ₹1.77
- Book value / share
- ₹17.03
- ROE
- 10.38%
- ROCE
- 18.68%
- ROA
- 4.36%
- Debt / equity
- 0x
- Dividend yield
- 0%
- EBITDA margin
- 3.22%
- 52-week range
- ₹40 – ₹62
Ratios are computed from filed results and the last recorded price. Not investment advice.
Financial Performance
Mar 2026In the year ended Mar 2026, Syschem (India) Ltd (SYSCHEM) reported revenue of ₹574 crore, net profit of ₹11 crore and earnings per share of ₹2.23. That compares with revenue of ₹332 crore in Mar 2025. Figures are standalone, as filed with the exchanges.
In the quarter ended Mar 2026, revenue was ₹219.35 crore and net profit ₹1.74 crore (standalone).
| Metric | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue (₹ cr) | 59 | 114 | 199 | 332 | 574 |
| Net profit (₹ cr) | -2 | 5 | 3 | 0 | 11 |
| EPS (₹) | -0.59 | 1.13 | 0.69 | 0.11 | 2.23 |
| Measure | 10Y | 5Y | 3Y | 1Y |
|---|---|---|---|---|
| Sales growth | 67.52% | 34.42% | 80.54% | 65.42% |
| Profit growth | - | - | - | -83.33% |
Ownership Summary
Jun 2026As of Jun 2026, promoters hold 60.15% of Syschem (India) Ltd (SYSCHEM) (down 0.71 pp QoQ) and domestic institutional investors (DII) hold 0.16%. Market capitalisation was ₹228 crore on 10 Jul 2026. Shareholding is filed quarterly with BSE and NSE; Solomo carries every filing back to Mar 2001.
Largest disclosed public shareholders in Jun 2026: ASHIKA GLOBAL FINANCE PVT. LTD. 4.43%, KAMAL GADALAY 1.35%, SURESH GADALAY 1.29%. Only stakes above the 1% disclosure threshold are named in filings.
| Quarter | Promoter | Pledged | FII | DII | Public |
|---|---|---|---|---|---|
| Jun 2026 | 60.15% | - | - | 0.16% | 39.85% |
| Mar 2026 | 60.86% | - | - | 0.16% | 39.14% |
| Dec 2025 | 56.71% | - | - | 0.18% | 43.29% |
| Sep 2025 | 56.71% | - | - | 0.18% | 43.29% |
| Jun 2025 | 56.71% | - | - | 0.18% | 43.29% |
| Mar 2025 | 57.02% | - | - | 0.18% | 42.98% |
| Dec 2024 | 53.17% | - | - | 0.2% | 46.83% |
| Sep 2024 | 53.17% | - | - | 0.2% | 46.83% |